The low prevalence of colonic serrated adenocarcinoma with high KRAS mutational status at Cipto Mangunkusumo Hospital, Indonesia
| Autor: | Diah Rini Handjari, Nur Rahadiani, Marini Stephanie, Ening Krisnuhoni |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Colorectal cancer serrated adenocarcinoma Prevalence medicine.disease_cause law.invention 03 medical and health sciences 0302 clinical medicine Tumor budding Growth factor receptor law Internal medicine medicine Polymerase chain reaction lcsh:R5-920 business.industry KRAS mutation Anatomical pathology General Medicine medicine.disease digestive system diseases 030104 developmental biology colon cancer 030220 oncology & carcinogenesis Adenocarcinoma KRAS lcsh:Medicine (General) business |
| Zdroj: | Medical Journal of Indonesia, Vol 27, Iss 3 (2018) |
| ISSN: | 2252-8083 0853-1773 |
| DOI: | 10.13181/mji.v27i3.1719 |
| Popis: | Background: Serrated adenocarcinoma (SA), a subtype of colorectal carcinoma, and the KRAS mutation, a strong marker for the patient’s response to anti-epidermal growth factor receptor therapy, have a clinical importance because of its progressive nature and tendency for chemoresistance. The purposes of this study were to (1) determine the prevalence of SA, (2) evaluate the histomorphological characteristics of SA and classical adenocarcinoma based on its prognostic factors, (3) determine the prevalence of the KRAS mutation in SA cases, and (4) identify the main characteristics of SA cases and classical adenocarcinoma with a KRAS mutation.Methods: This study was conducted by reviewing hematoxylin-eosin-stained slides of colorectal carcinoma (CRC) cases from January 2013 to July 2015 at the Department of Anatomical Pathology Cipto Mangunkusumo General Hospital. The final diagnosis of SA was based on the Tuppurainen et al criteria and the KRAS mutation was evaluated using real-time polymerase chain reaction.Results: Among the 117 adenocarcinoma cases, there were 41 unequivocal SA, 11 equivocal SA, and 65 classical adenocarcinoma. The prevalence rates of unequivocal and equivocal SA among all CRC cases were 7.7% and 2.1%, respectively. There were 11 (28.2%) cases of wild-type KRAS and 28 (71.7%) cases of mutated KRAS among all unequivocal SA cases. Tumor budding (TB) was the predominant prognostic factor.Conclusion: The prevalence of SA among all CRC cases was 7.7%. The KRAS mutation was found in almost three-quarters of all SA cases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|